Cancer belongs to multifactorial diseases characterized by uncontrolled growth and proliferation of abnormal cells. Breast cancer, non-small cell lung cancer, and colorectal cancer are the most frequently diagnosed malignancies with a high mortality rate. These carcinomas typically contain multiple genetically distinct subpopulations of tumor cells leading to tumor heterogeneity, which promotes the aggressiveness of the disease. Early diagnosis is necessary to increase patient progression-free survival. Particularly, miRNAs present in exosomes derived from tumors represent potential biomarkers suitable for early cancer diagnosis. Identification of miRNAs by liquid biopsy enables a personalized approach with the subsequent better clinical management of patients. This review article highlights the potential of circulating exosomal miRNAs in early breast, non-small cell lung, and colorectal cancer diagnosis.

Department of Clinical Genetics St Elizabeth's Cancer Institute Bratislava Slovak Republic

Zobrazit více v PubMed

Cancer Burden Statistics and Trends Across Europe. 2020. p. ECIS. https://ecis.jrc.ec.europa.eu/

Cao J, Yan Q. Cancer epigenetics, tumor immunity, and immunotherapy. Trends in Cancer. 2020;6:580–592. doi: 10.1016/j.trecan.2020.02.003. PubMed DOI PMC

Takeshima H, Ushijima T. Accumulation of genetic and epigenetic alterations in normal cells and cancer risk. Precis Oncol. 2019;3:1–8. doi: 10.1038/s41698-019-0079-0. PubMed DOI PMC

Eu Commision. Council conclusions on personalised medicine for patients. Off J Eur Union. 2015;58:1–32.

Gambardella V, Tarazona N, Cejalvo JM, Lombardi P, Huerta M, Roselló S, Fleitas T, Roda D, Cervantes A. Personalized medicine: recent progress in cancer therapy. cancers (Basel) 2020;12:1009. doi: 10.3390/cancers12041009. PubMed DOI PMC

Awad K, Dalby M, Cree I, Challoner B, Ghosh S, Thurston D. The precision medicine approach to cancer therapy: part 1-solid tumours. Pharm J. 2019:303. doi: 10.1211/PJ.2019.20207119. DOI

Goossens N, Nakagawa S, Sun X, Hoshida Y. Cancer biomarker discovery and validation. Transl Cancer Res. 2015;4:256. doi: 10.3978/j.issn.2218-676X.2015.06.04. PubMed DOI PMC

Jadli AS, Ballasy N, Edalat P, Patel VB. Inside(sight) of tiny communicator: exosome biogenesis, secretion, and uptake. Mol Cell Biochem. 2020;467:77–94. doi: 10.1007/s11010-020-03703-z. PubMed DOI

Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkin-Smith GK, Ayre DC, Bach JM, Bachurski D, Baharvand H, Balaj L, Baldacchino S, Bauer NN, Baxter AA, Bebawy M, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7:1535750. doi: 10.1080/20013078.2018.1535750. PubMed DOI PMC

Farooqi AA, Desai NN, Qureshi MZ, Librelotto DRN, Gasparri ML, Bishayee A, Nabavi SM, Curti V, Daglia M. Exosome biogenesis, bioactivities and functions as new delivery systems of natural compounds. Biotechnol Adv. 2018;36:328–34. doi: 10.1016/j.biotechadv.2017.12.010. PubMed DOI

Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K. The MicroRNA Spectrum in 12 Body Fluids. Clin Chem. 2010;56:1733–1741. doi: 10.1373/clinchem.2010.147405. PubMed DOI PMC

Mathieu M, Martin-Jaular L, Lavieu G, Théry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol. 2019;21:9–17. doi: 10.1038/s41556-018-0250-9. PubMed DOI

Stefanius K, Servage K, Orth K. Exosomes in cancer development. Curr Opin Genet Dev. 2021;66:83–92. doi: 10.1016/j.gde.2020.12.018. PubMed DOI

Zhang L, Yu D. Exosomes in cancer development, metastasis, and immunity. Biochim Biophys Acta - Rev Cancer. 2019;1871:455–68. doi: 10.1016/j.bbcan.2019.04.004. PubMed DOI PMC

Paskeh MDA, Entezari M, Mirzaei S, Zabolian A, Saleki H, Naghdi MJ, Sabet S, Khoshbakht MA, Hashemi M, Hushmandi K, Sethi G, Zarrabi A, Kumar AP, Tan SC, Papadakis M, Alexiou A, Islam MA, Mostafavi E, Ashrafizadeh M. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. J Hematol Oncol. 2022;15:1–39. doi: 10.1186/s13045-022-01305-4. PubMed DOI PMC

Vallabhaneni KC, Hassler MY, Abraham A, Whitt J, Mo YY, Atfi A, Pochampally R. Mesenchymal stem/stromal cells under stress increase osteosarcoma migration and apoptosis resistance via extracellular vesicle mediated communication. PLoS One. 2016;11:e0166027. doi: 10.1371/journal.pone.0166027. PubMed DOI PMC

Guo J, Duan Z, Zhang C, Wang W, He H, Liu Y, Wu P, Wang S, Song M, Chen H, Chen C, Si Q, Xiang R, Luo Y. Mouse 4T1 breast cancer cell-derived exosomes induce proinflammatory cytokine production in macrophages via miR-183. J Immunol. 2020;205:2916–2925. doi: 10.4049/jimmunol.1901104. PubMed DOI

Caivano A, Laurenzana I, De Luca L, La Rocca F, Simeon V, Trino S, D'Auria F, Traficante A, Maietti M, Izzo T, D'Arena G, Mansueto G, Pietrantuono G, Laurenti L, Musto P, Del Vecchio L. High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders. Tumor Biol. 2015;36:9739–9752. doi: 10.1007/s13277-015-3741-3. PubMed DOI

Yamamoto CM, Oakes ML, Murakami T, Muto MG, Berkowitz RS, Ng SW. Comparison of benign peritoneal fluid- and ovarian cancer ascites-derived extracellular vesicle RNA biomarkers. J Ovarian Res. 2018;11:1–9. doi: 10.1186/s13048-018-0391-2. PubMed DOI PMC

Preethi KA, Selvakumar SC, Ross K, Jayaraman S, Tusubira D, Sekar D. Liquid biopsy: Exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer. Mol Cancer. 2022;21:1–15. doi: 10.1186/s12943-022-01525-9. PubMed DOI PMC

Sun Z, Shi K, Yang S, Liu J, Zhou Q, Wang G, Song J, Li Z, Zhang Z, Yuan W. Effect of exosomal miRNA on cancer biology and clinical applications. Mol Cancer. 2018;17:1–19. doi: 10.1186/s12943-018-0897-7. PubMed DOI PMC

Bayraktar R, VanRoosbroeck K, Calin GA. Cell-to-cell communication : microRNAs as hormones. Mol Oncol. 2017;11:1673–1686. doi: 10.1002/1878-0261.12144. PubMed DOI PMC

Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012;4:143–59. doi: 10.1002/emmm.201100209. PubMed DOI PMC

Giza DE, Vasilescu C, Calin GA. Key principles of miRNA involvement in human diseases. Discoveries. 2014;2:e34. doi: 10.15190/d.2014.26. PubMed DOI PMC

Cortez MA, Bueso-ramos C, Ferdin J, Lopez-berestein G, Anil K, Calin GA. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8:467–477. doi: 10.1038/nrclinonc.2011.76. PubMed DOI PMC

Wang X, Tian L, Lu J, Ng IOL. Exosomes and cancer - Diagnostic and prognostic biomarkers and therapeutic vehicle. Oncogenesis. 2022;11:1–12. doi: 10.1038/s41389-022-00431-5. PubMed DOI PMC

Bautista-Sánchez D, Arriaga-Canon C, Pedroza-Torres A, De La Rosa-Velázquez IA, González-Barrios R, Contreras-Espinosa L, Montiel-Manríquez R, Castro-Hernández C, Fragoso-Ontiveros V, Álvarez-Gómez RM, Herrera LA. The promising role of miR-21 as a cancer biomarker and its importance in RNA-based therapeutics. Mol Ther - Nucleic Acids. 2020;20:409–420. doi: 10.1016/j.omtn.2020.03.003. PubMed DOI PMC

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–749. doi: 10.3322/caac.21660. PubMed DOI

De Silva S, Tennekoon KH, Karunanayake EH. Overview of the genetic basis toward early detection of breast cancer. Breast Cancer Targets Ther. 2019;11:71–80. doi: 10.2147/BCTT.S185870. PubMed DOI PMC

Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, Shi B. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015;5:2929. PubMed PMC

Wu Q, Li J, Zhu S, Wu J, Chen C, Liu Q, Wei W, Zhang Y, Sun S. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study. Oncotarget. 2017;8:27990. doi: 10.18632/oncotarget.15856. PubMed DOI PMC

Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, Im SA, Krug D, Kunz WG, Loi S, Penault-Llorca F, Ricke J, Robson M, Rugo HS, Saura C, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32:1475–95. doi: 10.1016/j.annonc.2021.09.019. PubMed DOI

Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065–7070. doi: 10.1158/0008-5472.CAN-05-1783. PubMed DOI

Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–838. doi: 10.1038/nature03702. PubMed DOI

Cookson VJ, Bentley MA, Hogan BV, Horgan K, Hayward BE, Hazelwood LD, Hughes TA. Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours. Cell Oncol. 2012;35:301–308. doi: 10.1007/s13402-012-0089-1. PubMed DOI

Ni Q, Stevic I, Pan C, Müller V, Oliviera-Ferrer L, Pantel K, Schwarzenbach H. Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients. Sci Rep. 2018;8:1–10. doi: 10.1038/s41598-018-31108-y. PubMed DOI PMC

Li M, Zhou Y, Xia T, Zhou X, Huang Z, Zhang H, Zhu W, Ding Q, Wang S. Circulating microRNAs from the miR-106a-363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer. Breast Cancer Res Treat. 2018;170:257–270. doi: 10.1007/s10549-018-4757-3. PubMed DOI PMC

Zhu Y, Dou H, Liu Y, Yu P, Li F, Wang Y, Xiao M. Breast Cancer Exosome-Derived miR-425–5p Induces cancer-associated fibroblast-like properties in human mammary fibroblasts by TGF β 1/ROS signaling pathway. Oxid Med Cell Longev. 2022:2022. doi: 10.1155/2022/5266627. PubMed DOI PMC

Mihelich BL, Dambal S, Lin S, Nonn L. miR-182, of the miR-183 cluster family, is packaged in exosomes and is detected in human exosomes from serum, breast cells and prostate cells. Oncol Lett. 2016;12:1197–203. doi: 10.3892/ol.2016.4710. PubMed DOI PMC

Yoshikawa M, Iinuma H, Umemoto Y, Yanagisawa T, Matsumoto A, Jinno H. Exosome-encapsulated microRNA-223-3p as a minimally invasive biomarker for the early detection of invasive breast cancer. Oncol Lett. 2018;15:9584–9592. doi: 10.3892/ol.2018.8457. PubMed DOI PMC

Sun Y, Wang M, Lin G, Sun S, Li X, Qi J, Li J. Serum MicroRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One. 2012;7:e47003. doi: 10.1371/journal.pone.0047003. PubMed DOI PMC

Hannafon BN, Trigoso YD, Calloway CL, Zhao YD, Lum DH, Welm AL, Zhao ZJ, Blick KE, Dooley WC, Ding WQ. Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Res. 2016;18:1–14. doi: 10.1186/s13058-016-0753-x. PubMed DOI PMC

Li S, Yang X, Yang J, Zhen J, Zhang D. Serum microRNA-21 as a potential diagnostic biomarker for breast cancer: a systematic review and meta-analysis. Clin Exp Med. 2016;16:29–35. doi: 10.1007/s10238-014-0332-3. PubMed DOI

Markou A, Zavridou M, Sourvinou I, Yousef G, Kounelis S, Malamos N, Georgoulias V, Lianidou E. Direct Comparison of metastasis-related miRNAs expression levels in circulating tumor cells, corresponding plasma, and primary tumors of breast cancer patients. Clin Chem. 2016;62:1002–1011. doi: 10.1373/clinchem.2015.253716. PubMed DOI

Nguyen THN, Nguyen TTN, Nguyen TTM, Nguyen LHM, Huynh LH, Phan HN, Nguyen HT. Panels of circulating microRNAs as potential diagnostic biomarkers for breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2022;196:1–15. doi: 10.1007/s10549-022-06728-8. PubMed DOI

Feng YH, Tsao CJ. Emerging role of microRNA-21 in cancer (Review) Biomed Reports. 2016;5:395–402. doi: 10.3892/br.2016.747. PubMed DOI PMC

Wang H, Tan Z, Hu H, Liu H, Wu T, Zheng C, Wang X, Luo Z, Wang J, Liu S, Lu Z, Tu J. MicroRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1. BMC Cancer. 2019;19:1–13. doi: 10.1186/s12885-019-5951-3. PubMed DOI PMC

Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008;14:2348–2360. doi: 10.1261/rna.1034808. PubMed DOI PMC

Yuan X, Qian N, Ling S, Li Y, Sun W, Li J, Du R, Zhong G, Liu C, Yu G, Cao D, Liu Z, Wang Y, Qi Z, Yao Y, Wang F, Liu J, Hao S, Jin X, et al. Breast cancer exosomes contribute to pre-metastatic niche formation and promote bone metastasis of tumor cells. Theranostics. 2021;11:1429. doi: 10.7150/thno.45351. PubMed DOI PMC

Xue X, Liu Y, Wang Y, Meng M, Wang K, Zang X, Zhao S, Sun X, Cui L, Pan L, Liu S. MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN. Oncotarget. 2016;7:84508. doi: 10.18632/oncotarget.13022. PubMed DOI PMC

Pfeffer SR, Yang CH, Pfeffer LM. The Role of miR-21 in Cancer. Drug Dev Res. 2015;76:270–277. doi: 10.1002/ddr.21257. PubMed DOI

Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D, Cheng JQ. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem. 2010;285:17869–17879. doi: 10.1074/jbc.M110.101055. PubMed DOI PMC

Rodríguez-Martínez A, De Miguel-Pérez D, Ortega FG, García-Puche JL, Robles-Fernández I, Exposito J, Martorell-Marugan J, Carmona-Sáez P, Garrido-Navas MDC, Rolfo C, Ilyine H, Lorente JA, Legueren M, Serrano MJ. Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy. Breast Cancer Res. 2019;21:1–9. doi: 10.1186/s13058-019-1109-0. PubMed DOI PMC

Zhu Y, Dou H, Liu Y, Yu P, Li F, Wang Y, Xiao M. Identification of serum exosomal miR-148a as a novel prognostic biomarker for breast cancer. Eur Rev Med Pharmacol Sci. 2020;24:7303–7309. PubMed

van Schooneveld E, Wouters MCA, Van der Auwera I, Peeters DJ, Wildiers H, Van Dam PA, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Res. 2012;14:1–16. doi: 10.1186/bcr3127. PubMed DOI PMC

Zelli V, Compagnoni C, Capelli R, Cannita K, Sidoni T, Ficorella C, Capalbo C, Zazzeroni F, Tessitore A, Alesse E. Circulating micrornas as prognostic and therapeutic biomarkers in breast cancer molecular subtypes. J Pers Med. 2020;10:1–18. doi: 10.3390/jpm10030098. PubMed DOI PMC

Sisti JS, Collins LC, Beck AH, Tamimi RM, Rosner BA, Eliassen AH. Reproductive risk factors in relation to molecular subtypes of breast cancer: Results from the nurses' health studies. Int J Cancer. 2016;138:2346–2356. doi: 10.1002/ijc.29968. PubMed DOI PMC

Howard FM, Olopade OI. Epidemiology of triple-negative breast cancer: a review. Cancer J (United States) 2021;27:8–16. doi: 10.1097/PPO.0000000000000500. PubMed DOI

Eichelser C, Stückrath I, Müller V, Milde-Langosch K, Wikman H, Pantel K, Schwarzenbach H, Eichelser C, Stückrath I, Müller V, Milde-Langosch K, Wikman H, Pantel K, Schwarzenbach H. Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget. 2014;5:9650–9663. doi: 10.18632/oncotarget.2520. PubMed DOI PMC

Stevic I, Müller V, Weber K, Fasching PA, Karn T, Marmé F, Schem C, Stickeler E, Denkert C, Van Mackelenbergh M, Salat C, Schneeweiss A, Pantel K, Loibl S, Untch M, Schwarzenbach H. Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Med. 2018;16:1–16. doi: 10.1186/s12916-018-1163-y. PubMed DOI PMC

Shankar A, Dubey A, Saini D, Singh M, Prasad CP, Roy S, Bharati SJ, Rinki M, Singh N, Seth T, Khanna M, Sethi N, Kumar S, Sirohi B, Mohan A, Guleria R, Rath GK. Environmental and occupational determinants of lung cancer. Transl Lung Cancer Res. 2019;8:S31. doi: 10.21037/tlcr.2019.03.05. PubMed DOI PMC

Corrales L, Rosell R, Cardona AF, Martín C, Zatarain-Barrón ZL, Arrieta O. Lung cancer in never smokers: The role of different risk factors other than tobacco smoking. Crit Rev Oncol Hematol. 2020;148:102895. doi: 10.1016/j.critrevonc.2020.102895. PubMed DOI

Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2018;52:103–109. doi: 10.1016/j.semcancer.2017.11.019. PubMed DOI PMC

Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446–454. doi: 10.1038/nature25183. PubMed DOI

Naylor EC. Adjuvant Therapy for Stage I and II Non-Small Cell Lung Cancer. Surg Oncol Clin N Am. 2016;25:585–99. doi: 10.1016/j.soc.2016.03.003. PubMed DOI

Chen P, Li Y, Liu R, Xie Y, Jin Y, Wang M, Yu Z, Wang W, Luo X. Non-small cell lung cancer-derived exosomes promote proliferation, phagocytosis, and secretion of microglia via exosomal microRNA in the metastatic microenvironment. Transl Oncol. 2023;27:101594. doi: 10.1016/j.tranon.2022.101594. PubMed DOI PMC

Liang G, Meng W, Huang X, Zhu W, Yin C, Wang C, Fassan M, Yu Y, Kudo M, Xiao S, Zhao C, Zou P, Wang Y, Li X, Croce CM, Cui R. MiR-196b-5p-mediated downregulation of TSPAN12 and GATA6 promotes tumor progression in non-small cell lung cancer. Proc Natl Acad Sci U S A. 2020;117:4347–4357. doi: 10.1073/pnas.1917531117. PubMed DOI PMC

Roush S, Slack FJ. The let-7 family of microRNAs. Trends Cell Biol. 2008;18:505–516. doi: 10.1016/j.tcb.2008.07.007. PubMed DOI

He XY, Chen JX, Zhang Z, Li CL, LePeng Q, Peng HM. The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice. J Cancer Res Clin Oncol. 2010;136:1023–1028. doi: 10.1007/s00432-009-0747-5. PubMed DOI PMC

Guo L, Chen C, Shi M, Wang F, Chen X, Diao D, Hu M, Yu M, Qian L, Guo N. Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition. Oncogene. 2013;32:5272–5282. doi: 10.1038/onc.2012.573. PubMed DOI

Yeh CT, Huang WC, Rao YK, Ye M, Lee WH, Wang LS, Tzeng DTW, Wu CH, Shieh YS, Huang CYF, Chen YJ, Hsiao M, Wu ATH, Yang Z, Tzeng YM. A sesquiterpene lactone antrocin from Antrodia camphorata negatively modulates JAK2/STAT3 signaling via microRNA let-7c and induces apoptosis in lung cancer cells. Carcinogenesis. 2013;34:2918–2928. doi: 10.1093/carcin/bgt255. PubMed DOI

Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, Chin L, Brown D, Slack FJ. The let-7 MicroRNA Represses Cell Proliferation Pathways in Human Cells. Cancer Res. 2007;67:7713–7722. doi: 10.1158/0008-5472.CAN-07-1083. PubMed DOI

Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. RAS Is Regulated by the let-7 MicroRNA Family. Cell. 2005;120:635–647. doi: 10.1016/j.cell.2005.01.014. PubMed DOI

Zhao B, Han H, Chen J, Zhang Z, Li S, Fang F, Zheng Q, Ma Y, Zhang J, Wu N, Yang Y. MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3. Cancer Lett. 2014;342:43–51. doi: 10.1016/j.canlet.2013.08.030. PubMed DOI

Jin X, Chen Y, Chen H, Fei S, Chen D, Cai X, Liu L, Lin B, Su H, Zhao L, Su M, Pan H, Shen L, Xie D, Xie C. Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing. Clin Cancer Res. 2017;23:5311–5319. doi: 10.1158/1078-0432.CCR-17-0577. PubMed DOI

Zhang Z, Tang Y, Song X, Xie L, Zhao S, Song X. Tumor-derived exosomal miRNAs as diagnostic biomarkers in non-small cell lung cancer. Front Oncol. 2020;10:2236. doi: 10.3389/fonc.2020.560025. PubMed DOI PMC

Zhang Y, Zhang Y, Yin Y, Li S. Detection of circulating exosomal miR-17-5p serves as a novel non-invasive diagnostic marker for non-small cell lung cancer patients. Pathol - Res Pract. 2019;215:152466. doi: 10.1016/j.prp.2019.152466. PubMed DOI

Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y, Takahashi T. A Polycistronic MicroRNA Cluster, miR-17-92, Is Overexpressed in Human Lung Cancers and Enhances Cell Proliferation. Cancer Res. 2005;65:9628–32. doi: 10.1158/0008-5472.CAN-05-2352. PubMed DOI

Taguchi A, Yanagisawa K, Tanaka M, Cao K, Matsuyama Y, Goto H, Takahashi T. Identification of Hypoxia-Inducible Factor-1α as a Novel Target for miR-17-92 MicroRNA Cluster. Cancer Res. 2008;68:5540–5. doi: 10.1158/0008-5472.CAN-07-6460. PubMed DOI

Grillari J, Hackl M, Grillari-Voglauer R. miR-17-92 cluster: Ups and downs in cancer and aging. Biogerontology. 2010;11:501–506. doi: 10.1007/s10522-010-9272-9. PubMed DOI PMC

Chen Q, Si Q, Xiao S, Xie Q, Lin J, Wang C, Chen L, Chen Q, Wang L. Prognostic significance of serum miR-17-5p in lung cancer. Med Oncol. 2013;30:1–6. doi: 10.1007/s12032-012-0353-2. PubMed DOI

Lai X, Friedman A. Exosomal miRs in lung cancer: a mathematical model. PLoS One. 2016;11:e0167706. doi: 10.1371/journal.pone.0167706. PubMed DOI PMC

Rabinowits G, Gerçel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal MicroRNA: A Diagnostic Marker for Lung Cancer. Clin Lung Cancer. 2009;10:42–46. doi: 10.3816/CLC.2009.n.006. PubMed DOI

Poroyko V, Mirzapoiazova T, Nam A, Mambetsariev I, Mambetsariev B, Wu X, Husain A, Vokes EE, Wheeler DL, Salgia R. Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients. Oncotarget. 2018;9:19793. doi: 10.18632/oncotarget.24857. PubMed DOI PMC

Zhang YK, Zhu WY, He JY, Chen DD, Huang YY, Le HB, Liu XG. MiRNAs expression profiling to distinguish lung squamous-cell carcinoma from adenocarcinoma subtypes. J Cancer Res Clin Oncol. 2012;138:1641–1650. doi: 10.1007/s00432-012-1240-0. PubMed DOI PMC

Zhou X, Wen W, Shan X, Zhu W, Xu J, Guo R, Cheng W, Wang F, Qi LW, Chen Y, Huang Z, Wang T, Zhu D, Liu P, Shu Y. A six-microRNA panel in plasma was identified as a potential biomarker for lung adenocarcinoma diagnosis. Oncotarget. 2017;8:6513. doi: 10.18632/oncotarget.14311. PubMed DOI PMC

Xu Z, Wang Z, Sun H, Xin H. Evaluation of Exosomal miRNA in Blood as a Potential Diagnostic Biomarker for Human Non-Small Cell Lung Cancer. Med Sci Monit Int Med J Exp Clin Res. 2020:26. doi: 10.12659/MSM.924721. PubMed DOI PMC

Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi DJ, John A, Lim YC, Kaderi Kibria KM, Mohiuddin AKM, Ming LC, Goh KW, Hadi MA. Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies. Cancers (Basel) 2022;14:1732. doi: 10.3390/cancers14071732. PubMed DOI PMC

Siegel RL, Miller KD, Sauer AG, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70:145–164. https://doi.org/10.3322/caac.21601, https://doi.org/10.3322/caac.21590. PubMed DOI

Zhang Y, Guo L, Li Y, Feng GH, Teng F, Li W, Zhou Q. MicroRNA-494 promotes cancer progression and targets adenomatous polyposis coli in colorectal cancer. Mol Cancer. 2018;17:1. doi: 10.1186/s12943-017-0753-1. PubMed DOI PMC

Li KP, Fang YP, Liao JQ, Duan JD, Feng LG, Luo XZ, Liang ZJ. Upregulation of miR-598 promotes cell proliferation and cell cycle progression in human colorectal carcinoma by suppressing INPP5E expression. Mol Med Rep. 2018;17:2991–7. doi: 10.3892/mmr.2017.8207. PubMed DOI PMC

Lu D, Tang L, Zhuang Y, Zhao P. MiR-17-3P regulates the proliferation and survival of colon cancer cells by targeting Par4. Mol Med Rep. 2018;17:618–623. doi: 10.3892/mmr.2017.7863. PubMed DOI

Wang S, Zeng Y, Zhou JM, Nie SL, Peng Q, Gong J, Huo JR. MicroRNA-1246 promotes growth and metastasis of colorectal cancer cells involving CCNG2 reduction. Mol Med Rep. 2016;13:273–280. doi: 10.3892/mmr.2015.4557. PubMed DOI

Matsumura T, Sugimachi K, Iinuma H, Takahashi Y, Kurashige J, Sawada G, Ueda M, Uchi R, Ueo H, Takano Y, Shinden Y, Eguchi H, Yamamoto H, Doki Y, Mori M, Ochiya T, Mimori K. Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br J Cancer. 2015;113:275–281. doi: 10.1038/bjc.2015.201. PubMed DOI PMC

Chen M, Xu R, Rai A, Suwakulsiri W, Izumikawa K, Ishikawa H, Greening DW, Takahashi N, Simpson RJ. Distinct shed microvesicle and exosome microRNA signatures reveal diagnostic markers for colorectal cancer. PLoS One. 2019;14:e0210003. doi: 10.1371/journal.pone.0210003. PubMed DOI PMC

Slattery ML, Mullany LE, Sakoda L, Samowitz WS, Wolff RK, Stevens JR, Herrick JS. The NF-κB signalling pathway in colorectal cancer: associations between dysregulated gene and miRNA expression. J Cancer Res Clin Oncol. 2018;144:269–283. doi: 10.1007/s00432-017-2548-6. PubMed DOI PMC

Shao Y, Chen T, Zheng X, Yang S, Xu K, Chen X, Xu F, Wang L, Shen Y, Wang T, Zhang M, Hu W, Ye C, Yu XF, Shao J, Zheng S. Colorectal cancer-derived small extracellular vesicles establish an inflammatory premetastatic niche in liver metastasis. Carcinogenesis. 2018;39:1368–1379. doi: 10.1093/carcin/bgy115. PubMed DOI

Uratani R, Toiyama Y, Kitajima T, Kawamura M, Hiro J, Kobayashi M, Tanaka K, Inoue Y, Mohri Y, Mori T, Kato T, Goel A, Kusunoki M. Diagnostic Potential of Cell-Free and Exosomal MicroRNAs in the Identification of Patients with High-Risk Colorectal Adenomas. PLoS One. 2016;11:e0160722. doi: 10.1371/journal.pone.0160722. PubMed DOI PMC

Zou SL, Chen YL, Ge ZZ, Qu YY, Cao Y, Kang ZX. Downregulation of serum exosomal miR-150-5p is associated with poor prognosis in patients with colorectal cancer. Cancer Biomarkers. 2019;26:69–77. doi: 10.3233/CBM-190156. PubMed DOI

Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, Gunji T, Ohta H, Okamoto H, Sonoda H, Watanabe M, Nakagama H, Yokota J, Kohno T, Tsuchiya N. Circulating Exosomal microRNAs as Biomarkers of Colon Cancer. PLoS One. 2014;9:e92921. doi: 10.1371/journal.pone.0092921. PubMed DOI PMC

Dohmen J, Semaan A, Kobilay M, Zaleski M, Branchi V, Schlierf A, Hettwer K, Uhlig S, Hartmann G, Kalff JC, Matthaei H, Lingohr P, Holdenrieder S. Diagnostic Potential of Exosomal microRNAs in Colorectal Cancer. Diagnostics. 2022;12:1413. doi: 10.3390/diagnostics12061413. PubMed DOI PMC

Min L, Zhu S, Chen L, Liu X, Wei R, Zhao L, Yang Y, Zhang Z, Kong G, Li P, Zhang S. Evaluation of circulating small extracellular vesicles derived miRNAs as biomarkers of early colon cancer: a comparison with plasma total miRNAs. J Extracell Vesicles. 2019:8. doi: 10.1080/20013078.2019.1643670. PubMed DOI PMC

Yan S, Han B, Gao S, Wang X, Wang Z, Wang F, Zhang J, Xu D, Sun B. Exosome-encapsulated microRNAs as circulating biomarkers for colorectal cancer. Oncotarget. 2017;8:60149. doi: 10.18632/oncotarget.18557. PubMed DOI PMC

Liu C, Eng C, Shen J, Lu Y, Yoko T, Mehdizadeh A, Chang GJ, Rodriguez-Bigas MA, Li Y, Chang P, Mao Y, Hassan MM, Wang F, Li D. Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer. Oncotarget. 2016;7:76250. doi: 10.18632/oncotarget.12841. PubMed DOI PMC

Peng ZY, Gu RH, Yan B. Downregulation of exosome-encapsulated miR-548c-5p is associated with poor prognosis in colorectal cancer. J Cell Biochem. 2019;120:1457–63. doi: 10.1002/jcb.27291. PubMed DOI

Vu T, Datta PK. Regulation of EMT in Colorectal Cancer: A Culprit in Metastasis. Cancers (Basel) 2017;9:171. doi: 10.3390/cancers9120171. PubMed DOI PMC

Zhou JJ, Zheng S, Sun LF, Zheng L. MicroRNA regulation network in colorectal cancer metastasis. World J Biol Chem. 2014;5:301. doi: 10.4331/wjbc.v5.i3.301. PubMed DOI PMC

Yang N, Zhu S, Lv X, Qiao Y, Liu YJ, Chen J. MicroRNAs: Pleiotropic regulators in the tumor microenvironment. Front Immunol. 2018;9:2491. doi: 10.3389/fimmu.2018.02491. PubMed DOI PMC

De Greef K, Rolfo C, Russo A, Chapelle T, Bronte G, Passiglia F, Coelho A, Papadimitriou K, Peeters M. Multisciplinary management of patients with liver metastasis from colorectal cancer. World J Gastroenterol. 2016;22:7215. doi: 10.3748/wjg.v22.i32.7215. PubMed DOI PMC

Hofsli E, Sjursen W, Prestvik WS, Johansen J, Rye M, Tranø G, Wasmuth HH, Hatlevoll I, Thommesen L. Identification of serum microRNA profiles in colon cancer. Br J Cancer. 2013;108:1712–1719. doi: 10.1038/bjc.2013.121. PubMed DOI PMC

Tang Y, Zhao Y, Song X, Song X, Niu L, Xie L. Tumor-derived exosomal miRNA-320d as a biomarker for metastatic colorectal cancer. J Clin Lab Anal. 2019;33:e23004. doi: 10.1002/jcla.23004. PubMed DOI PMC

Takano Y, Masuda T, Iinuma H, Yamaguchi R, Sato K, Tobo T, Hirata H, Kuroda Y, Nambara S, Hayashi N, Iguchi T, Ito S, Eguchi H, Ochiya T, Yanaga K, Miyano S, Mimori K. Circulating exosomal microRNA-203 is associated with metastasis possibly via inducing tumor-associated macrophages in colorectal cancer. Oncotarget. 2017;8:78598. doi: 10.18632/oncotarget.20009. PubMed DOI PMC

Yan S, Jiang Y, Liang C, Cheng M, Jin C, Duan Q, Xu D, Yang L, Zhang X, Ren B, Jin P. Exosomal miR-6803-5p as potential diagnostic and prognostic marker in colorectal cancer. J Cell Biochem. 2018;119:4113–4119. doi: 10.1002/jcb.26609. PubMed DOI